News

Here's what is coming soon to NeurologyLive.

The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]

Between PREVENT baseline and end, mean EDSS and Hauser Ambulation Index scores improved with eculizumab (Soliris; Alexion) monotherapy and deteriorated with placebo alone.

Following MDS 2021, we compiled a roundup of some of our discussions with experts in the Parkinson disease and movement disorders space in one convenient location.

Lucas M. Donovan, MD, MS, discussed key takeaways from a recent study evaluating the integration of telehealth during the COVID-19 pandemic.

The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending September 25, 2021. [WATCH TIME: 4 minutes]

The findings identified Th2-related cytokines as characterizing for the prognosis of acute episodes of NMOSD at 1 month and found serum NfL to be a likely biomarker of disease severity at attack.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 24, 2021.

The expanded access program is designed to provide individuals with ALS who are not eligible to enroll in the Healey ALS Platform Trial access to CNM-Au8.

The director of the UAB Huntington's Disease Clinic offered his insight on a recent assessment of HD genetic testing at HDSA Centers of Excellence, and the associated costs for patients.

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed his presentation at MDS 2021, which highlighted the therapeutic benefit of omaveloxolone in Friedreich ataxia. [WATCH TIME: 2 minutes]

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Patricia Bobryk, MHS, PT, MSCS, ATP.

Data suggest that certain activities of daily living are more prevalent depending on whether the caregiver is a man or a woman.

Helen Colquhoun, MD, vice president of early development at Sage Therapeutics, commented on results from a phase 2 study in which patients receiving SAGE-324 showed a significant decrease in ET.

When asked about developments, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel commented on the need to identify disease-modifying therapies. [WATCH TIME: 3 minutes]

At the Third International Congress on the Future of Neurology, experts in the care of sleep medicine offered insight into sleep and the glymphatic system’s roles in the development of dementias.

The director of the Women’s Prevention Center at Cleveland Clinic discussed why understanding genetics may help drug development of Alzheimer disease treatments. [WATCH TIME: 2 minutes]

More than 80% of those with NMOSD experienced disease relapse 6 months after discontinuation of immunosuppressive therapy.

Data were collected from the MDS’s membership worldwide, assessing current practices, concerns, and barriers to genetic testing.

Data found that synchronic dance classes conducted through Zoom may be particularly effective for patients who live remotely.

Following his presentation at the MDS Society Virtual Congress 2021, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center discussed his views on the use of medical cannabis. [WATCH TIME: 3 minutes]

On World Narcolepsy Day 2021, get a recap of the latest advances in narcolepsy that you might have missed over the last few months, compiled all into one place by the NeurologyLive team.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed future neuroimaging projects the center is evaluating and where the focus turns to next. [WATCH TIME: 3 minutes]

The director of the Women’s Movement Prevention Center at Cleveland Clinic discussed her new study, and the current knowledge of the role genetics play in Alzheimer disease risk.

Patients were evaluated at day 29 for change in TETRAS item 4 score change from baseline.

Over a 12-month stretch, patients with spinocerebellar ataxia type 2 treated with riluzole showed significant worsening in Composite Cerebellar Functional Severity Score.

On World Alzheimer Day 2021, the NeurologyLive team has compiled interviews with experts in the field of Alzheimer disease care to offer up a summary of the latest in treatment and the remaining challenges.

Next steps for medical cannabis will need to include how cannabinoids affect the brain, according to the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel.

The director of The Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic discussed her recently awarded NIH grant and her work to understand why women are more likely to be impacted by Alzheimer disease.